BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
19 déc. 2022 07h00 HE
|
BioXcel Therapeutics
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia Estimated 100 million annual Alzheimer’s-related agitation...
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
01 déc. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
30 nov. 2022 07h00 HE
|
BioXcel Therapeutics
SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use Top-line pivotal data expected in 1H 2023 Estimated 23 million annual agitation episodes in the home-setting would more...
BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
14 nov. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
10 nov. 2022 07h00 HE
|
BioXcel Therapeutics
IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies ...
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
27 oct. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
05 oct. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
09 août 2022 07h00 HE
|
BioXcel Therapeutics
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal...
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
03 août 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...